What are the symptoms of a blood clot caused by immunomodulatory drug (IMiD)‐based regimens?
ChatGPT said:
Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- IMiD Blood Clot Symptoms?
IMiD Blood Clot Symptoms?
What are IMiD blood clot symptoms? When IMiD therapies such as Revlimid, Thalidomide, and Pomalidomide cause a blood clot in a MM patient, what happens?
I asked this question because multiple myeloma MM patients who develop blood clots don’t know what to expect. At least I didn’t when I developed a blood clot. I walked around in pain for a couple of days before I thought to ask my oncologist about the swelling in my calf.
Also, I didn’t know that a first DVT significantly increased my risk for a second blood clot.
Immunomodulatory drugs (IMiDs) — such as thalidomide, lenalidomide, and pomalidomide — are effective for multiple myeloma but significantly increase the risk of venous thromboembolism (VTE), especially when combined with dexamethasone or chemotherapy. The most common type of clot in this setting is deep vein thrombosis (DVT), though pulmonary embolism (PE) can also occur.
Here are the key symptoms to watch for, grouped by the type of clot:
🦵 Deep Vein Thrombosis (DVT) — usually in the leg
-
Swelling in one leg (occasionally both) — often sudden and persistent
-
Pain or tenderness in the calf or thigh, sometimes described as cramping or soreness
-
Warmth over the affected area
-
Red or discolored skin
-
Visible surface veins or a feeling of tightness in the leg
⚠️ Symptoms can be mild or mistaken for muscle strain; any new, unexplained swelling or pain in the leg of a myeloma patient on IMiDs should be evaluated promptly.
🫁 Pulmonary Embolism (PE) — when a clot travels to the lungs
-
Sudden shortness of breath
-
Chest pain (sharp, often worse with deep breaths or coughing)
-
Rapid heartbeat (tachycardia)
-
Coughing, sometimes with blood (hemoptysis)
-
Lightheadedness, dizziness, or fainting
⚠️ These symptoms are medical emergencies — immediate evaluation is critical.
🖐️ Less common sites of thrombosis
-
Upper-extremity DVTs (especially if a central venous catheter is present): arm swelling, pain, or redness
-
Superficial vein thrombosis: tenderness and redness along a visible vein
-
Arterial thrombosis (rare): cold, pale, or painful limb, or sudden neurological symptoms if cerebral vessels are affected
💡 Clinical context
-
Risk is highest during the first few months of IMiD therapy.
-
Risk increases with high-dose dexamethasone, erythropoiesis-stimulating agents, immobility, obesity, or prior clot history.
-
Prophylaxis (aspirin, LMWH, or DOAC) is usually prescribed based on risk assessment (IMWG guidelines).
While Dr. Google can be wrong when diagnosing medical problems, I think the explanation above may point those with a DVT in the right direction. Yes, follow up with your oncologist. Once I talked to my onc. and figured out what was going on, a few days in the hospital on heparin therapy resolved my DVT.
Feel free to email me at David.PeopleBeatingCancer@gmail.com with questions you have about your blood clot.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network [Guidelines]
Highlights:
This expert consensus introduces key updates, including the simplification of risk stratification by grouping intermediate- and high-risk patients with multiple myeloma (MM) using the IMPEDE-VTE score, and advocates for the use of factor Xa inhibitors alongside low-molecular-weight heparins (LMWH) for primary thromboprophylaxis.
A recent Expert Panel Consensus on Practice Guidelines for the Prevention and Treatment of Venous Thromboembolism in Patients with Multiple Myeloma, on behalf of the European Myeloma Network, has launched evidence-based recommendations for preventing and treating venous thromboembolism (VTE) in MM patients. The main recommendations were:
· Recommendations 1 and 2: The panel recommends providing educational materials to patients with MM on VTE (Grade 1A), and implementing systematic VTE risk assessment for all MM patients at the initial diagnosis, treatment initiation, relapse/progression, and whenever treatment regimens are modified (Grade 1A).
· Recommendations 3 and 4: The panel recommends the implementation of the IMPEDE‐VTE score for VTE risk assessment in all patients with MM (Grade 1B), and the stratification of patients into two risk groups as either high/intermediate or low risk for VTE (Grade 2A).
· Recommendations 5 and 6: The panel suggests patients who receive immunomodulatory drug (IMiD)‐based regimens or carfilzomib combinations should be stratified as high/intermediate risk for VTE (Grade 2Β), and suggests risk assessment for VTE upon primary diagnosis and antimyeloma treatment initiation, following induction completion or disease remission, at diagnosis of disease progression or recurrence, when modifications of therapeutic lines are scheduled (Grade 2B)
· Recommendation 7: The panel recommends pharmacological thromboprophylaxis with direct anti‐Xa agents or LMWH to patients classified as high/intermediate risk for VTE (Grade 1B).
· Recommendation 8 and 9: The panel recommends the regular assessment of bleeding risk for patients at high/intermediate risk for VTE scheduled for pharmacological prophylaxis (Grade 1A), and recommends low‐dose aspirin for patients classified as low risk (Grade 2B).
· Recommendation 10: The panel recommends applying pharmacological thromboprophylaxis for at least 6 months from the last risk evaluation (no grade of recommendation)
The recommendations of thromboprophylaxis and treatment of VTE in patients with MM do not differ from other clinical scenarios, recommending a minimum duration of 6 months for antithrombotic treatment in patients with VTE and MM and the extension of the antithrombotic treatment beyond 6 months in patients with active MM (Grade 1A) or in patients receiving ongoing IMiD or carfilzomib therapy. A reduced dose of apixaban (2.5 mg twice daily) can be used in these patients.
Finally, regarding the prophylaxis and treatment of catheter-related VTE, routine pharmacological prophylaxis is not recommended for preventing catheter-related VTE. A minimum duration of anticoagulation of 3 months is recommended for symptomatic catheter‐related VTE in patients with MM (Grade 2C).
IMiD blood clot symptoms IMiD blood clot symptoms IMiD blood clot symptoms